{"slug":"retatrutide","verification":{"valid":false,"broken_at":6,"reason":"hash mismatch"},"count":10,"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/42250575/","title":"Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial","quote":"Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial","summary":"2026 Lancet phase 3 trial (TRANSCEND-T2D-1) on retatrutide efficacy/safety in T2D patients.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T16:59:28.284Z","link_status":"ok","quote_status":"verified","prev":"genesis","hash":"df8055142eadabf7d24e2f23e04866ae06fcff7b1651d65d2b383de14f67ebd8"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40728138/","title":"Efficacy and safety of retatrutide for the treatment of obesity","quote":"This systematic review assessed the safety and efficacy of retatrutide for obesity treatment using available clinical trial data.","summary":"2025 systematic review on retatrutide safety/efficacy for obesity.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T16:59:28.284Z","link_status":"ok","quote_status":"verified","prev":"df8055142eadabf7d24e2f23e04866ae06fcff7b1651d65d2b383de14f67ebd8","hash":"c967d92d24a7584a0661998f5f859935393e31e887b1fcd49302bfcc28a63120"},{"id":"s3","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/39817343/","title":"Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity: a systematic review and meta-analysis","quote":"In conclusion our analysis found retatrutide to be clinically and statistically better than placebo in the various studies outcomes.","summary":"2025 meta-analysis showing retatrutide superior to placebo for obesity.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T16:59:28.284Z","link_status":"ok","quote_status":"verified","prev":"c967d92d24a7584a0661998f5f859935393e31e887b1fcd49302bfcc28a63120","hash":"5b897b8c865f133b1ccb2b3ca4ad5552a703054ae8df4d0e5e2b2f352289ea6b"},{"id":"s4","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40291085/","title":"Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist, for the treatment of obesity: a systematic review and meta-analysis","quote":"Retatrutide demonstrated significant improvements in body weight and metabolic outcomes among adults with obesity and had an appropriate safety profile.","summary":"2025 meta-analysis on retatrutide for obesity treatment.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T16:59:28.284Z","link_status":"ok","quote_status":"verified","prev":"5b897b8c865f133b1ccb2b3ca4ad5552a703054ae8df4d0e5e2b2f352289ea6b","hash":"894a8378b761e3dbe9712cf88f12b43698950a6fc5eb1c75379bfdb457e3e9e6"},{"id":"s5","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40563436/","title":"Retatrutide-A Game Changer in Obesity Pharmacotherapy","quote":"This review synthesizes findings from preclinical and clinical studies, highlighting retatrutide's mechanisms, efficacy, and safety profile.","summary":"2025 review on retatrutide mechanisms, efficacy, and safety.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T16:59:28.284Z","link_status":"ok","quote_status":"verified","prev":"894a8378b761e3dbe9712cf88f12b43698950a6fc5eb1c75379bfdb457e3e9e6","hash":"beaa8c68dae730464fd3282304a7f9e27396f03351c3ae690b82e2abee1becfb"},{"id":"s6","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40609566/","title":"Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial","quote":"In adults with type 2 diabetes, retatrutide significantly improved total body fat mass reduction compared with placebo and dulaglutide.","summary":"2025 phase 2 substudy on retatrutide effects on body composition in T2D.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T16:59:28.284Z","link_status":"ok","quote_status":"verified","prev":"beaa8c68dae730464fd3282304a7f9e27396f03351c3ae690b82e2abee1becfb","hash":"6986319f262946376b00ea616b8614d5089e29289a6362c38691ba7afdcfed39"},{"id":"s7","type":"pubmed","url":"https://clinicaltrials.gov/study/NCT05882045","title":"A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3)","quote":"The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiovascular disease.","summary":"Ongoing TRIUMPH-3 phase 3 trial (last update 2026) for retatrutide in obesity with CVD.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T16:59:28.284Z","link_status":"ok","quote_status":"unverified","prev":"6986319f262946376b00ea616b8614d5089e29289a6362c38691ba7afdcfed39","hash":"397ba2c51b294d919cc41ed0526b427a3dac07b01cb0fdf95602412edc398d38"},{"id":"s8","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/41090431/","title":"Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials","quote":"Retatrutide, a novel synthetic molecule, is a triple agonist activating the glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1 and glucagon receptors. The TRIUMPH clinical development program evaluates its safety and efficacy concurrently for the treatment of obesity and two related complications-obstructive sleep apnea (OSA) and knee osteoarthritis (OA). A novel basket trial design simultaneously evaluates retatrutide treatment across these multiple adiposity-related disease states.","summary":"Describes the design of Phase 3 TRIUMPH trials for retatrutide in obesity, OSA, and knee OA using a basket trial approach.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T16:59:46.247Z","link_status":"ok","quote_status":"verified","prev":"397ba2c51b294d919cc41ed0526b427a3dac07b01cb0fdf95602412edc398d38","hash":"3f0458a22c0cf3b2f3f02893a8c6f364b998f87d37bb478093f479ff12e1bd9e"},{"id":"s9","type":"pubmed","url":"https://clinicaltrials.gov/study/NCT05936151","title":"A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes","quote":"The main purpose of this study is to investigate the effect of retatrutide on renal function in participants with overweight or obesity and chronic kidney disease (CKD), with or without Type 2 Diabetes (T2D).","summary":"Phase 2b trial examining retatrutide's impact on renal function in overweight/obese patients with CKD ± T2D.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T16:59:46.247Z","link_status":"ok","quote_status":"unverified","prev":"3f0458a22c0cf3b2f3f02893a8c6f364b998f87d37bb478093f479ff12e1bd9e","hash":"3ed1814e3170f9d2ceb83059fefc0fcccf9b1edf6949d420edc241395739d23b"},{"id":"s10","type":"pubmed","url":"https://clinicaltrials.gov/study/NCT07232719","title":"A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight (TRIUMPH-8)","quote":"The purpose of this study is to evaluate the efficacy and safety of retatrutide compared with placebo for body weight reduction.","summary":"Phase 3b trial of retatrutide vs placebo for weight reduction in obesity/overweight without T2D.","author":"","publisher":"","date":"","claim_ids":[],"found_by":"grok-4.3","extra":{},"accessed_at":"2026-06-29T16:59:46.247Z","link_status":"ok","quote_status":"unverified","prev":"3ed1814e3170f9d2ceb83059fefc0fcccf9b1edf6949d420edc241395739d23b","hash":"5991724bd0539547aa4d742cd634247033cb5129d0dbbbf24190715859e2711c"}]}